Hims & Hers Health, Inc. (HIMS)
| Market Cap | 8.21B -31.6% |
| Revenue (ttm) | 2.37B +32.8% |
| Net Income | -13.24M |
| EPS | -0.06 |
| Shares Out | 231.46M |
| PE Ratio | n/a |
| Forward PE | 66.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,903,480 |
| Open | 32.60 |
| Previous Close | 31.89 |
| Day's Range | 32.59 - 35.60 |
| 52-Week Range | 13.74 - 70.43 |
| Beta | 2.40 |
| Analysts | Hold |
| Price Target | 27.32 (-22.98%) |
| Earnings Date | Aug 3, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $27.32, which is a decrease of -22.98% from the latest price.
News
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Barclays Raises HIMS Stock Price Target on Strong GLP-1 Growth
Shares of Hims & Hers Health ($HIMS) rose 1.7% in pre-market trading after gaining 1.3% on Wednesday, following a bullish analyst update from Barclays. Four-star-rated analyst Glen Santangelo raised h...
Hims & Hers price target raised to $39 from $29 at Barclays
Barclays raised the firm’s price target on Hims & Hers (HIMS) to $39 from $29 and keeps an Overweight rating on the shares. A combination of weight loss and other…
Hims & Hers Stock Forecast: Leerink Analyst Sees Long-Term Peptide Upside
Hims & Hers Health ($HIMS) was up 4.3% on Tuesday after Leerink Partners analyst Michael Cherny reiterated a Hold rating and $25 price target. He said that the company’s long‑term…
Hims & Hers Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approval, with all proposals passing by majority or plurality. Stockholders could submit questions virtually, with responses to follow post-meeting.
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Him...
Hims & Hers Health Transcript: 2026 Evercore Global TMT Conference
Ambitious 2030 targets are set, driven by global expansion, specialty growth, and technology investments. Recent acquisitions and partnerships, especially with Eucalyptus and Novo Nordisk, accelerate international reach and deepen consumer engagement. AI and data are central to platform differentiation and operational efficiency.
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
BERLIN--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In...
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
SYDNEY--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus – the parent company of Juniper, Pilot, Kin, and Software – advancing its position as the world's largest ...
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
TOKYO--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its form...
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company...
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on t...
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the...
Hims & Hers Health Slides: Investor presentation
Hims & Hers Health has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
HIMS Stock Crashed after Earnings. I Don’t Think the Growth Story Is Broken
The meltdown in Hims & Hers Health ($HIMS) stock has raised doubts about the company’s momentum. The post-earnings sell-off since its Q1 report came earlier this month shows the market…
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's blockbuster drug Ozempic, through its ...
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada....
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible cus...
Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% co...
Here’s Why Hims & Hers Stock Tumbled 9% Today, 5/18/26
Hims & Hers ($HIMS) shares fell 8.5% on Monday after the company said it plans to raise $300 million through a private offering of convertible senior notes due 2032. The…
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggre...
Hims & Hers Drops After Earnings Miss & HIMS Options Trade
Marley Kayden breaks down Him & Hers (HIMS) after the company missed on both earnings and revenue. She explains how the end of the weight-loss drug shortage hurt their momentum, despite a rise in subs...
Tuesday's Morning Movers: HIMS, ASTS & ONON Down on Earnings
Diane King Hall talks about notable earnings movers as markets open lower. Hims & Hers (HIMS) fell after a surprise loss as U.S. sales decline.
U.S.-Iran Ceasefire on "Life Support," HIMS & ASTS Earnings Sell-Off
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines c...
Hims & Hers tumbles 15% after earnings miss as GLP-1 transition weighs on results
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped...